Efficient access to highly pure β-amyloid peptide by optimized solid-phase synthesis.

Area of Science:

• Biochemistry
• Neuroscience
• Peptide Synthesis

Background:

• Alzheimer's disease research is significantly hindered by the difficulty in synthesizing full-length amyloid-beta (Aβ) peptides.
• Previous methods struggled with reproducibility and scalability, limiting in-depth study of Aβ's role in Alzheimer's disease.

Purpose of the Study:

• To develop a feasible and reproducible method for the large-scale synthesis of biologically active full-length Aβ peptides.
• To overcome common challenges in peptide synthesis, such as aggregation and residual deletion, particularly for phenylalanine residues.

Main Methods:

• Utilized manual Fmoc solid phase peptide synthesis.
• Employed dimethyl sulfoxide as an anti-aggregation solvent and to facilitate double-coupling of phenylalanine residues.
• Confirmed amyloidogenic activity using thioflavin T assay, transmission electron microscopy, and electrophoresis.

Main Results:

• Successfully synthesized full-length Aβ peptides with high purity and in large quantities.
• The synthesized Aβ peptides demonstrated confirmed amyloidogenic activity.
• The developed method proved reliable and reproducible for producing active Aβ.

Conclusions:

• The novel Fmoc solid phase peptide synthesis procedure offers a reliable solution for producing biologically active Aβ peptides.
• This advancement facilitates further research into Alzheimer's disease mechanisms and potential therapeutic strategies.
• The method's efficiency in overcoming synthesis challenges makes it valuable for the broader scientific community.